Aurinia Pharmaceuticals Inc. Increase (Decrease) in Prepaid Expense
Aurinia Pharmaceuticals Inc. (AUPH) reported Increase (Decrease) in Prepaid Expense of $5.03 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidExpense · last filed 2026-08-06
- Aurinia Pharmaceuticals Inc. increase (decrease) in prepaid expense for the quarter ending 2026-06-30 was $5.98M, a 545.20% increase year-over-year.
- Aurinia Pharmaceuticals Inc. increase (decrease) in prepaid expense for the quarter ending 2026-03-31 was -$950.00K.
- Aurinia Pharmaceuticals Inc. increase (decrease) in prepaid expense for the quarter ending 2025-12-31 was -$4.58M.
- Aurinia Pharmaceuticals Inc. increase (decrease) in prepaid expense for the quarter ending 2025-09-30 was $4.17M, a 145.64% increase year-over-year.
- Aurinia Pharmaceuticals Inc. increase (decrease) in prepaid expense for fiscal 2025 was -$5.52M, a 401.09% decline from fiscal 2024.
- Aurinia Pharmaceuticals Inc. increase (decrease) in prepaid expense for fiscal 2024 was $1.83M.
- Aurinia Pharmaceuticals Inc. increase (decrease) in prepaid expense for fiscal 2023 was -$4.40M, a 282.99% decline from fiscal 2022.
- Aurinia Pharmaceuticals Inc. increase (decrease) in prepaid expense for fiscal 2022 was $2.40M, a 54.94% decline from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense 3 month | Increase (Decrease) in Prepaid Expense 6 month | Increase (Decrease) in Prepaid Expense 9 month | Increase (Decrease) in Prepaid Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $5.03M 10-Q · filed 2026-08-06 | $449.00K derived: sum of 3 quarters · filed 2026-08-06 | $4.62M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$950.00K 10-Q · filed 2026-05-07 | -$5.53M derived: sum of 2 quarters · filed 2026-05-07 | -$1.37M derived: sum of 3 quarters · filed 2026-05-07 | -$439.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$4.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$416.00K derived: sum of 2 quarters · filed 2026-02-26 | $511.00K derived: sum of 3 quarters · filed 2026-08-06 | -$5.52M 10-K · filed 2026-02-26 |
| 2025-09-30 | $4.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $5.09M derived: sum of 2 quarters · filed 2026-08-06 | -$940.00K 10-Q · filed 2025-11-04 | -$5.11M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $927.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$5.11M 10-Q · filed 2026-08-06 | -$9.27M derived: sum of 3 quarters · filed 2026-08-06 | -$7.58M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$6.03M 10-Q · filed 2026-05-07 | -$10.20M derived: sum of 2 quarters · filed 2026-05-07 | -$8.50M derived: sum of 3 quarters · filed 2026-05-07 | -$3.33M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$4.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$2.47M derived: sum of 2 quarters · filed 2026-02-26 | $2.71M derived: sum of 3 quarters · filed 2026-02-26 | $1.83M 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $6.87M derived: sum of 2 quarters · filed 2025-11-04 | $6.00M 10-Q · filed 2025-11-04 | -$1.29M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $5.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $4.30M 10-Q · filed 2025-07-31 | -$2.98M derived: sum of 3 quarters · filed 2026-02-26 | $2.28M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$873.00K 10-Q · filed 2025-05-12 | -$8.16M derived: sum of 2 quarters · filed 2026-02-26 | -$2.90M derived: sum of 3 quarters · filed 2026-02-26 | -$1.68M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$7.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$2.02M derived: sum of 2 quarters · filed 2026-02-26 | -$811.00K derived: sum of 3 quarters · filed 2026-02-26 | -$4.40M 10-K · filed 2026-02-26 |
| 2023-09-30 | $5.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $6.48M derived: sum of 2 quarters · filed 2024-11-07 | $2.89M 10-Q · filed 2024-11-07 | $1.83M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $1.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$2.37M 10-Q · filed 2024-08-01 | -$3.43M derived: sum of 3 quarters · filed 2025-02-27 | -$4.88M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$3.59M 10-Q · filed 2024-05-02 | -$4.64M derived: sum of 2 quarters · filed 2025-02-27 | -$6.10M derived: sum of 3 quarters · filed 2025-02-27 | -$877.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$1.06M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$2.51M derived: sum of 2 quarters · filed 2025-02-27 | $2.71M derived: sum of 3 quarters · filed 2025-02-27 | $2.40M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$1.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $3.77M derived: sum of 2 quarters · filed 2023-11-02 | $3.46M 10-Q · filed 2023-11-02 | $2.25M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $5.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $4.91M 10-Q · filed 2023-08-03 | $3.71M derived: sum of 3 quarters · filed 2024-02-15 | $8.26M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | -$307.00K 10-Q · filed 2023-05-04 | -$1.51M derived: sum of 2 quarters · filed 2024-02-15 | $3.04M derived: sum of 3 quarters · filed 2024-02-15 | $5.34M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | -$1.21M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $3.35M derived: sum of 2 quarters · filed 2024-02-15 | $5.64M derived: sum of 3 quarters · filed 2024-02-15 | $5.33M 10-K · filed 2024-02-15 |
| 2021-09-30 | $4.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $6.85M derived: sum of 2 quarters · filed 2022-11-03 | $6.54M 10-Q · filed 2022-11-03 | $257.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $2.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $1.99M 10-Q · filed 2022-08-04 | -$4.30M derived: sum of 3 quarters · filed 2023-02-28 | -$4.98M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$308.00K 10-Q · filed 2022-05-10 | -$6.59M derived: sum of 2 quarters · filed 2023-02-28 | -$7.28M derived: sum of 3 quarters · filed 2023-02-28 | -$5.53M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | -$6.28M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$6.97M derived: sum of 2 quarters · filed 2023-02-28 | -$5.22M derived: sum of 3 quarters · filed 2023-02-28 | -$2.56M 10-K · filed 2023-02-28 |
| 2020-09-30 | -$686.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $1.06M derived: sum of 2 quarters · filed 2021-11-03 | $3.73M 10-Q · filed 2021-11-03 | |
| 2020-06-30 | $1.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $4.41M 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $2.66M 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | $1.83M 10-K · filed 2022-02-28 | |||
| 2018-12-31 | $5.00M 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |